# Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.

> **NCT05669417** · PHASE2,PHASE3 · TERMINATED · sponsor: **HagaZiekenhuis** · enrollment: 265 (actual)

## Conditions studied

- Atrial Fibrillation New Onset

## Interventions

- **DRUG:** Magnesium sulfate

## Key facts

- **NCT ID:** NCT05669417
- **Lead sponsor:** HagaZiekenhuis
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-08-01
- **Primary completion:** 2023-07-17
- **Final completion:** 2023-08-06
- **Target enrollment:** 265 (ACTUAL)
- **Why stopped:** Futility after interim analysis
- **Last updated:** 2024-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669417, "Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05669417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*